Autres langues IRLAB Therapeutics AB

Actions

IRLAB A

SE0012675361

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:33 26/04/2024			Varia. 5j.	Varia. 1 janv.
10,25 ^SEK	-8,48%		-22,35%	+36,67%

22/03	IRLAB Therapeutics reçoit le compte-rendu de la réunion de fin de phase 2 confirmant l'alignement avec la FDA sur le programme de phase III pour le mesdopetam	CI
19/03	IRLAB Therapeutics AB (publ) Le mesdopetam présente des propriétés antipsychotiques dans un modèle avancé de psychose de la maladie de Parkinson	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

IRLAB to present at Redeye Investor Forum	16/04
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	25/03
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	22/03
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	22/03
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	19/03
IRLAB Therapeutics : mesdopetam displays antipsychotic properties in an advanced model of Parkinson's disease psychosis	19/03
IRLAB’s mesdopetam displays antipsychotic properties in an advanced model of Parkinson’s disease psychosis	19/03
IRLAB to present at Life Science-dagen in Gothenburg and have a fireside chat with ABG	29/02
IRLAB to present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7	28/02
IRLAB to present clinical and preclinical data at the AD/PD™ 2024: 18th International Conference on Alzheimer’s & Parkinson’s Diseases	27/02
IRLAB has completed a successful End-of-Phase 2 meeting with the FDA on the design of the Phase III program for mesdopetam	22/02
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam	22/02
IRLAB's pioneering Phase IIb study with pirepemat, React-PD, provides new insights in specific Parkinson's patient population and enables a data driven prediction of study timelines	07/02
IRLAB publishes year-end report for the period January-December 2023	07/02
IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07/02
IRLAB’s pioneering Phase IIb study with pirepemat – React-PD – provides new insights in specific Parkinson’s patient population and enables a data driven prediction of study timelines	06/02
IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines	06/02
IRLAB, Invitation to the Year-end Report 2023 presentation and webcast	01/02
IRLAB: Invitation to the Year-end Report 2023 presentation and webcast	31/01
IRLAB Therapeutics AB(OM:IRLAB A) added to OMX Nordic Small Cap Index	04/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues IRLAB Therapeutics AB

Actions

IRLAB A

SE0012675361

Autres langues

Filtres